Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Niessner

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Cancer Treatment Reviews|January 23, 2026
Insights into RAS-driven melanoma and its therapeutic implicationsEftychia Chatziioannou, Konstantinos Lallas, Tobias Sinnberg, et al.
Cell Death & Disease|September 13, 2018
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugsElena Makino, Vanessa Gutmann, Corinna Kosnopfel, et al.
Cancers|December 9, 2023
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated MelanomaHeike Niessner, Anna Hüsch, Corinna Kosnopfel, et al.
Cancer Research Communications|September 7, 2023
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanomaTeresa M S Amaral, Marie-Christine Hoffmann, Tobias Sinnberg, et al.
International Journal of Molecular Sciences|November 9, 2024
Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic TargetMatti Böcker, Eftychia Chatziioannou, Heike Niessner, et al.
Pigment Cell & Melanoma Research|June 27, 2015
PTEN regulates IGF-1R-mediated therapy resistance in melanomaJun Wang, Tobias Sinnberg, Heike Niessner, et al.
International Journal of Cancer|February 11, 2012
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cellsSarah Schott, Heike Niessner, Tobias Sinnberg, et al.
Nutrients|August 10, 2021
Ex Vivo Evaluation of the Sepsis Triple Therapy High-Dose Vitamin C in Combination with Vitamin B1 and Hydrocortisone in a Human Peripheral Blood Mononuclear Cells (PBMCs) ModelAnnie Lauer, Markus Burkard, Heike Niessner, et al.
Oncotarget|April 19, 2017
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|January 23, 2026
Insights into RAS-driven melanoma and its therapeutic implicationsEftychia Chatziioannou, Konstantinos Lallas, Tobias Sinnberg, et al.
Cell Death & Disease|September 13, 2018
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugsElena Makino, Vanessa Gutmann, Corinna Kosnopfel, et al.
Cancers|December 9, 2023
Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated MelanomaHeike Niessner, Anna Hüsch, Corinna Kosnopfel, et al.
Cancer Research Communications|September 7, 2023
PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <i>In Vitro</i> and <i>In Vivo</i>Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2019
Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanomaTeresa M S Amaral, Marie-Christine Hoffmann, Tobias Sinnberg, et al.
International Journal of Molecular Sciences|November 9, 2024
Ecto-NOX Disulfide-Thiol Exchanger 2 (ENOX2/tNOX) Is a Potential Prognostic Marker in Primary Malignant Melanoma and May Serve as a Therapeutic TargetMatti Böcker, Eftychia Chatziioannou, Heike Niessner, et al.
Pigment Cell & Melanoma Research|June 27, 2015
PTEN regulates IGF-1R-mediated therapy resistance in melanomaJun Wang, Tobias Sinnberg, Heike Niessner, et al.
International Journal of Cancer|February 11, 2012
Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cellsSarah Schott, Heike Niessner, Tobias Sinnberg, et al.
Nutrients|August 10, 2021
Ex Vivo Evaluation of the Sepsis Triple Therapy High-Dose Vitamin C in Combination with Vitamin B1 and Hydrocortisone in a Human Peripheral Blood Mononuclear Cells (PBMCs) ModelAnnie Lauer, Markus Burkard, Heike Niessner, et al.
Oncotarget|April 19, 2017
Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseCorinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, et al.
Pageof 6